Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

ael. The study is comprised of two parts – the current dose escalation phase and a subsequent expansion phase at the highest tolerated dose found during the escalation phase. During the dose escalation phase, trial participants are recruited in cohorts of three patients at a time, and the dose is increased for each subsequent cohort depending on the safety and tolerability results of the previous cohort. To date, there have been no serious adverse events related to BL-8040, while the primary adverse event has been a minor and transient reaction at the injection site. The BL-8040 dosing level of the current study cohort is 1 mg/kg, with the highest planned study dose being 1.5 mg/kg.

"We are very excited about the initial results from the Phase 2 trial of BL-8040 in relapsed and refractory AML patients. This is one of our most promising clinical-stage assets, and these results provide further support for the potential of this unique drug," said Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx. "Although the trial is at an early stage and we have not yet completed the dose-escalation assessment, we already see impressive mobilization of cancer cells from the bone marrow into the blood stream at a rate that is markedly higher than that seen with other drugs tested for this indication. In addition, there are initial signs of robust apoptosis of cancer cells, similarly to what we have seen in pre-clinical studies.

"The dose escalation phase of the study requires a safety and tolerability assessment by an outside Data and Safety Monitoring Board prior to advancing to the next dose level, while the expansion phase will proceed at the optimal dose without the need for such assessment. Therefore, we expect the expansion phase of the study to proceed at a significantly faster pace than the dose escalation phase. We are looking forward to reporting further interim results at the end of the dose esca
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Research and Markets ... of the "North American Computerized Physician ... Physician Order Entry, Standalone Computerized Physician Order ... Forecast to 2019 " report to ... , The North American computerized ...
(Date:5/26/2015)... May 26, 2015  PAREXEL International Corporation (NASDAQ: ... at the Goldman Sachs Healthcare Conference in Palos Verdes, ... Executive Officer, will be making a presentation on PAREXEL ... Tuesday, June 9, 2015. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
(Date:5/26/2015)... today announced the launch of its initial public offering ... represent 25.6% of its outstanding common stock following its ... in connection with the offering. The initial public offering ... $17 per share. The underwriters for the offering will ... an additional 937,500 shares of EndoChoice common stock. EndoChoice ...
Breaking Medicine Technology:North American Computerized Physician Order Entry Market 2015-2019 2PAREXEL International To Present At Goldman Sachs Healthcare Conference 2EndoChoice Announces Launch of Its Initial Public Offering 2
... Roper Industries, Inc. (NYSE: ROP ) ... discuss first quarter 2011 results to 8:00 AM ET ... originally scheduled.  The call can be accessed via webcast ... using confirmation code 5338709.  Webcast information and conference call ...
... CINCINNATI, April 11, 2011 CarePoint ... Premier Infusion (Premier). Premier provides home infusion pharmacy ... related nursing services in the Atlanta, Georgia area. ... operations while CarePoint also continues to grow its ...
Cached Medicine Technology:CarePoint Partners Expands Texas Presence and Opens Georgia Market With Acquisition of Premier Infusion 2
(Date:5/26/2015)... May 26, 2015 Scientists at the ... way to help advanced mesothelioma patients benefit from immunotherapy; ... posted an article on the new research. Click ... the departments of thoracic surgery and pulmonology theorized that, ... an immune system attack, immunotherapy drugs might work better ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 ProTrailer ... for Final Cut Pro X . This ... to simple and elegantly styled text. , ProTrailer ... seconds. , ProTrailer Network can easily complement any form ... desired and within seconds can make professional looking openers. ...
(Date:5/26/2015)... Learning ZoneXpress is excited to announce a ... . These cards have been specifically designed for WIC, ... text, these new educational resources are extremely useful ... tips and suggestions to clients and provide an individualized ... MyPlate: Eat for a Healthy Baby Pregnancy Education Cards, ...
(Date:5/26/2015)... 2015 DENVER (May 26, 2015) – ... it is also experiencing many of the growing pains ... counterparts, one major issue that cannabis companies now have ... of paper and plastic that marijuana growers, dispensaries and ... waste we see the opportunity to enhance our environment ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 The European imaging ... suggests over 45% of healthcare providers plan to make purchases. ... latest industry report. Data collected from these participants show that ... pathology takes a back seat. , “Many imaging IT ... year,” said peer60 CEO Jeremy Bikman. “This report details the ...
Breaking Medicine News(10 mins):Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2Health News:Learning ZoneXpress Introduces New Educational Resource for WIC, SNAP-Ed, and EFNEP 2Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 2Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 3Health News:peer60 report: European Healthcare IT Imaging Purchases: 2015 2
... LONG BEACH, Calif., Nov. 6 A class action,lawsuit ... Court,against S&F Management Company, Inc.; S&F Management Company, LLC; ... facilities,around the state [See list by city at end ... his Attorney in Fact, Virginia Boone, on his behalf,and ...
... Helps Organizations Rapidly Identify High-Risk Cases, ... Underwriting, BIRMINGHAM, Ala., Nov. 6 ... and DST Health Solutions announced that 16,organizations ... that helps organizations rapidly identify at-risk patients ...
... hospital discharge rates in Raleigh and 6 ... ... has,participated in a seven-city study on the impact of new CPR techniques, ... 2005 CPR guidelines, according to the study authors in a,presentation at the ...
... Inc.,(NYSE: CSA ), a real estate investment trust ... profession, including medical,offices, ambulatory surgery and diagnostic centers, today ... Third Quarter 2007 Results Cogdell Spencer Inc. ... unit of $0.30 and net loss per share of ...
... Tezosentan didn,t change outcomes for patients with sudden, life-threatening ... -- An experimental kind of medication has failed ... heart failure, a new trial finds. , The drug, ... of major cardiovascular events, or cut their risk ...
... ... Encourages Consistent Exercise for Individuals and ... Families -, PITTSBURGH, Nov. ... maintaining a healthy,lifestyle. The Amerathon Club has introduced a new online and interactive,total wellness ...
Cached Medicine News:Health News:Class Action Lawsuit Filed Against 15 California Nursing Homes 2Health News:Class Action Lawsuit Filed Against 15 California Nursing Homes 3Health News:Sixteen Organizations Implement ACG Rx-PM Predictive Modeling from Johns Hopkins University, DST Health Solutions 2Health News:Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device 2Health News:Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device 3Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 2Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 3Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 4Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 5Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 6Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 7Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 8Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 9Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 10Health News:Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results 11Health News:Experimental Drug Fails Against Heart Failure 2Health News:Experimental Drug Fails Against Heart Failure 3Health News:Innovative Amerathon Club Website 'Virtual' Journey to Good Health 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: